Key facts
- This page summarizes David E. Lazar's Form 3 filing for Cyclacel Pharmaceuticals, Inc. (CYCC).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Jan 2025, 19:04.
David E. Lazar - 02 Jan 2025 Form 3 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- CYCC
- Reported as of
- 02 Jan 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 07 Jan 2025, 19:04:06 UTC
- Prior SEC filing
- 31 Dec 2024
- Next SEC filing
- 10 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ David E. Lazar
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David E. Lazar filed Form 3 for Cyclacel Pharmaceuticals, Inc. (CYCC) on 07 Jan 2025.
Change
- Previous filing in this sequence was filed on 31 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CYCC
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 02 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CYCC
holding
Derivative
Series C Convertible Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 02 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,650,000
- Exercise price
- Footnotes
- F2, F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
No shares of Common Stock are beneficially owned.
Footnote F2
On January 2, 2025, David E. Lazar (the "Reporting Person") and Cyclacel Pharmaceuticals, Inc. (the "Company"), entered into a securies purchase agreement pursuant to which the Reporting Person will acquire (i) an aggregate of 1,000,000 shares of the Company's Series C Convertible Preferred Stock (the "Series C Preferred Stock") at a price of $1.00 per share and (ii) an aggregate of 2,100,000 shares of the Company's Series D Convertible Preferred Stock (the "Series D Preferred Stock", and together with the Series C Preferred Stock, the "Preferred Stock") at a price of $1.00 per share. Each share of Series C Preferred Stock is convertible into 2.65 shares of the Company's Common Stock at any time, subject to certain ownership limitations. The initial closing took place on January 6, 2025, whereby the Reporting Person acquired 200,000 shares of Series C Preferred Stock for a total purchase price of $1,000,000.
Footnote F3
The Reporting Person will acquire the shares of Series D Preferred Stock at a subsequent closing, subject to satisfaction of certain closing conditions, for a total purchase price of $2,100,000. Each share of Series D Preferred Stock will be convertible into 110 shares of the Company's Common Stock at any time, subject to certain ownership limitations.
Footnote F4
The Series C Preferred Stock is perpetual and therefore has no expiration date.
Footnote F5
The shares of Series C Preferred Stock are convertible at the option of the Reporting Person for no additional consideration.